Drug intelligence / Profile preview

danazol + glucocorticoids

Development stage: Preclinical
Lead developer: Winthrop Company
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

A combination therapy consisting of danazol (a synthetic steroid derived from ethisterone with androgenic, antigonadotropic, and anti-estrogenic properties) and glucocorticoids. This combination has been studied for treating refractory autoimmune thrombocytopenia associated with systemic lupus erythematosus, where danazol is used as an adjunctive treatment in patients who failed to respond to high-dose glucocorticoids alone.

Targets

GR (Glucocorticoid receptor)PR (Progesterone receptor)AR (Adrenergic receptors)ER (Estrogen receptor)

Beyond the preview

Go deeper on danazol + glucocorticoids.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on danazol + glucocorticoids.

Explore the full profile